Business
Nephros Announces Launch of PluraPath™, a Real-Time, Portable, Water Pathogen Detection System
SOUTH ORANGE, NJ, Jan. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high
About this update from Nephros, Inc.
[{"type":"text","content":"SOUTH ORANGE, NJ, Jan. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced that it has formally launched PluraPathTM, the only commercially available portable water pathogen detection system designed to provide actionable data for infection control teams on up to 15 different pathogens from a single water sample, in approximately one hour. \n “In recognition of the large market need and opportunity, we are excited to launch our real-time, portable water pathogen detection system – PluraPathTM,” said Daron Evans, President and CEO of Nephros. “Often finding ourselves present during pathogen outbreaks, we recognized the need for faster, actionable data. Every hour of delay increases patient risk. Additionally, solely focusing on legionella misses additional pathogens that can contribute to making patients sick. Our PluraPathTM system evaluates up to 15 separate pathogens, including legionella, pseudomonas, shigella, salmonella, mycobacterium, E. coli., norovirus and other potentially dangerous bacterial and viral pathogens.” “Initially, we will be working with our strategic distributors to provide capability demonstrations to medical facilities across the country. The combination of rational, regimented pathogen testing, actively managed water disinfection programs, and the risk-based placement of point-of-use filtration provides enhanced protection for patients from the risks and illnesses associated with waterborne pathogens.” The PluraPathTM system uses quantitative polymerase chain reaction (qPCR) technology to provide estimated colony forming units per milliliter (CFU/ml) information to infection control teams on a real-time basis. Each assay has been developed to target specific DNA or RNA segments of the target pathogens. The system leverages Nephros’s proprietary ultrafiltration technology to concentrate the water sample and to decrease the lower limit of detection of pathogens in a 1 liter water sample. Nephros expects real-time data from the PluraPathTM to enable infection control teams to quickly assess potential risks throughout a medical facility, allowing teams to dynamically deploy resources and disinfec...